216 related articles for article (PubMed ID: 18841047)
1. Antiangiogenic therapy in malignant gliomas.
Norden AD; Drappatz J; Wen PY
Curr Opin Oncol; 2008 Nov; 20(6):652-61. PubMed ID: 18841047
[TBL] [Abstract][Full Text] [Related]
2. Primetime for antiangiogenic therapy.
Tabatabai G; Stupp R
Curr Opin Neurol; 2009 Dec; 22(6):639-44. PubMed ID: 19786873
[TBL] [Abstract][Full Text] [Related]
3. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues.
Dietrich J; Norden AD; Wen PY
Curr Opin Neurol; 2008 Dec; 21(6):736-44. PubMed ID: 19060566
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
de Groot JF; Yung WK
Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
7. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies for high-grade glioma.
Norden AD; Drappatz J; Wen PY
Nat Rev Neurol; 2009 Nov; 5(11):610-20. PubMed ID: 19826401
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
De Bonis P; Marziali G; Vigo V; Peraio S; Pompucci A; Anile C; Mangiola A
Expert Rev Neurother; 2013 Nov; 13(11):1263-70. PubMed ID: 24175724
[TBL] [Abstract][Full Text] [Related]
13. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Omuro AM; Delattre JY
Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
15. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
16. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
Wick W; Wick A; Weiler M; Weller M
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):136-43. PubMed ID: 26256461
[TBL] [Abstract][Full Text] [Related]
18. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
19. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
20. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.
Rege TA; Fears CY; Gladson CL
Neuro Oncol; 2005 Apr; 7(2):106-21. PubMed ID: 15831230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
